Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

3 clinical studies listed.

Filters:

Mantle-cell Lymphoma

Tundra lists 3 Mantle-cell Lymphoma clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT07029737

A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain

This is a single-arm, open-label, multicenter, non-indication seeking phase II trial to describe the efficacy and safety of patients with mantle cell lymphoma (MCL) receiving acalabrutinib in combination with R-CHOP for the front-line treatment of MCL in Spain. Acalabrutinib will be administered until disease progression if medically appropriate, along with R-CHOP based on institutional standards. After 6 cycles of acalabrutinib in combination with R-CHOP, subjects who tolerate treatment and not progressing, will then receive monotherapy acalabrutinib. In addition, subjects who achieve a response (PR or greater) will receive maintenance rituximab every other 28-day cycle for a maximum of 12 additional doses. Thereafter, subjects receive monotherapy acalabrutinib until disease progression or treatment discontinuation.

Gender: All

Ages: 18 Years - 130 Years

Updated: 2026-04-08

Mantle-cell Lymphoma
RECRUITING

NCT06564038

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

The purpose of this study is to assess the safety and efficacy of AZD0486 administered as monotherapy or in combination with other anticancer agents in participants with hematological malignancies.

Gender: All

Ages: 18 Years - Any

Updated: 2026-02-05

9 states

Chronic Lymphocytic Leukaemia
Small Lymphocytic Lymphoma
Mantle-cell Lymphoma
+2
RECRUITING

NCT05868395

Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma

Polatuzumab, bendamustine and rituximab in patients with relapsed/ refractory mantle cell lymphoma

Gender: All

Ages: 18 Years - 100 Years

Updated: 2024-05-29

Mantle-cell Lymphoma